Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

John Papp

Gastroenterology Grand Rapids, MI Medical Doctor

NPI 1417932872 CMS profile 18404

1179 E Paris Ave Se Ste 200, Grand Rapids, MI 49546

Open in the dashboard

General payments

$9,546

629 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, John Papp of Grand Rapids, MI is reported in the CMS Open Payments database as having received $9,546 across 629 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 80th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,449 78
2024 General $1,790 99
2023 General $2,318 161
2022 General $1,447 96
2021 General $541 42
2020 General $610 38
2019 General $1,390 115

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John Papp
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to John Papp were reported at $1,449. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year John Papp Gastroenterology median Middle half National median
2019 $1,390 $417 $126–$1,100 $163
2020 $610 $224 $74–$624 $114
2021 $541 $352 $106–$1,054 $132
2022 $1,447 $448 $129–$1,270 $149
2023 $2,318 $533 $150–$1,390 $160
2024 $1,790 $605 $160–$1,606 $164
2025 $1,449 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $2,412 159 payments
  2. Takeda Pharmaceuticals U.S.A., Inc. $1,715 117 payments
  3. Janssen Biotech, Inc. $1,160 72 payments
  4. Celgene Corporation $552 68 payments
  5. Pfizer Inc. $357 25 payments
  6. Salix Pharmaceuticals, a division of Bausch Health US, LLC $313 24 payments
  7. Merck Sharp & Dohme Corporation $279 23 payments
  8. Genzyme Corporation $230 14 payments
  9. Amgen Inc. $211 9 payments
  10. Regeneron Healthcare Solutions, Inc. $196 8 payments
  11. Other $2,120 110 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,386 622 payments
  2. Education $160 7 payments
Products named General payments · program years 2019–2025
  1. ENTYVIO $1,370 90 payments
  2. RINVOQ $1,122 56 payments
  3. STELARA $955 64 payments
  4. HUMIRA $724 42 payments
  5. ZEPOSIA $552 68 payments
  6. CREON $467 50 payments
  7. SKYRIZI $384 26 payments
  8. LINZESS $303 41 payments
  9. XELJANZ $289 22 payments
  10. XIFAXAN $260 20 payments
  11. Other $5,004 290 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 18 drugs

Part D claims

1,795

Median for Gastroenterology: 569

Drug cost

$826,994

Median for Gastroenterology: $104,976

Branded share of claims

29.1%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Stelara Ustekinumab Brand 22 $603,027
Humira Pen Adalimumab Brand 11 $78,056
Mesalamine Generic 40 $67,173
Mesalamine Er Mesalamine Brand 25 $17,750
Balsalazide Disodium Generic 65 $15,620
Omeprazole Generic 680 $14,208
Pantoprazole Sodium Generic 217 $5,585
Mesalamine Dr Mesalamine Brand 12 $4,876
Lansoprazole Generic 64 $3,611
Gavilyte-G Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 197 $3,528

The 10 drugs with the highest cost, of 18 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 26 billing codes

Paid by Medicare

$89,767

Medicare's payments for the services billed

Medicare patients

208

Average age 72

Services billed

1,028

109 women, 99 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 63%
Arthritis 48%
Ischemic heart disease 23%
Diabetes 22%
Chronic kidney disease 19%
Depression 18%
Atrial fibrillation 16%
Cancer 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 30 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ENTYVIO
  • Takeda Pharmaceuticals U.S.A., Inc. $414
$414 — —
OMVOH
  • Lilly USA, LLC $172
$172 — —
RINVOQ
  • AbbVie, Inc. $171
$171 — —
SKYRIZI
  • AbbVie, Inc. $107
$107 — —
STELARA
  • Janssen Biotech, Inc. $106
$106 22 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 30 with Patron

Records

629 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record